Clinical trial

Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer

NCT01532960

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention poly-ICLC Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention 9 Peptides from Her-2/neu, CEA, & CTA Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Peptide-tet Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2012-07-01

PhasePHASE1

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

poly-ICLCBIOLOGICAL

9 Peptides from Her-2/neu, CEA, & CTABIOLOGICAL

Peptide-tetBIOLOGICAL

Sponsors & collaborators

Craig L Slingluff, Jrlead sponsor

Mapped research locations

CharlottesvilleVirginia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01532960 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.